Determining pharmacotherapy options for behavioral disturbances in patients with developmental disabilities

Psychiatric Annals

Volumn 34, Issue 3, 2004, Pages 205-212

  Antochi, Ruxandra M ^a   Stavrakaki, Chrissoula ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c Child and Family Psychiatric Unit   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; FLUPHENAZINE; LITHIUM; MIRTAZAPINE; NADOLOL; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE ANTAGONIST; PAROXETINE; PROPRANOLOL; RISPERIDONE; SEROTONIN 1 AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZUCLOPENTHIXOL;

AGGRESSION; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DISEASE EXACERBATION; DYSKINESIA; EPILEPSY; EXTRAPYRAMIDAL SYNDROME; HOSTILITY; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; LESCH NYHAN SYNDROME; MENTAL INSTABILITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; PHARMACEUTICAL CARE; PRADER WILLI SYNDROME; SIDE EFFECT; STEREOTYPY; WEIGHT GAIN;

EID: 2042537315     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20040301-09     Document Type: Article

References (66)

1. Spreat S, Conroy JW, Jones JC. Use of psychotropic medications in Oklahoma: a statewide survey. Am J Ment Retard. 1997;102(1):80-85.
2. Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database Syst Rev. 2001;(3):CD000377.
3. Borthwick-Duffy SA. Epidemiology and prevalence of psychopathology in people with mental retardation. J Consult Clin Psychol. 1994;62(1):17-27.
4. PubMed. Available at: www.docguide.com and www.ncbi.nlm.nih.gov/PubMed. Accessed February 17, 2004.
5. Ovid Online. Available at: http://www.ovid.com/site/index.jsp. Accessed February 17, 2004.
6. Barron J, Sandman CA. Paradoxical excitement to sedative-hypnotics in mentally retarded clients. Am J Ment Defic. 1985;90(2):124-129.
7. Ghaziuddin N, Ghaziuddin M. Mania-like reaction induced by benzodiazepine withdrawal in a patient with mental retardation. Can J Psychiatry. 1990;35(70):612-613.
8. Ratey J, Sovner R, Parks A, Rogentine K. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. J Clin Psychiatry. 1991;52(4):159-162.
9. Ricketts RW, Goza AB, Ellis CR, et al. Clinical effects of buspirone on intractable self-injury in adults with mental retardation. J Am Acad Child Adolesc Psychiatry. 1994;33(2):270-276.
10. Lewis MH, Bodfish JW, Powell SB, Golden RN. Clomipramine treatment for stereotypy and related repetitive movement disorders associated with mental retardation. Am J Ment Retard. 1995;100(3):299-312.
11. Lewis MH, Bodfish JW, Powell SB, Parker DE, Golden RN. Clomipramine treatment for self-injurious behavior of individuals with mental retardation: a double-blind comparison with placebo. Am J Ment Retard. 1996;100(6):654-665.
12. Luiselli JK, Blew P, Thibadeau S. Therapeutic effects and long-term efficacy of antidepressant medication for persons with developmental disabilities. Behavioral assessment in two cases of treatment-resistant aggression and self-injury. Behav Modif. 2001;25(1):62-78.
13. Brasic JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1165-1166.
14. Ricketts RW, Goza AB, Ellis CR, et al. Fluoxetine treatment of severe self-injury in young adults with mental retardation. J Am Acad Child Adolesc Psychiatry. 1993;32(4):865-869.
15. Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard. 1998;102(5):427-437.
16. Campbell JJ 3rd, Duffy JD. Sertraline treatment of aggression in a developmentally disabled patient. J Clin Psychiatry. 1995;56(3):123-124.
17. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Cin Psychiatry. 1996;57(8):333-336.
18. Troisi A, Vicario E, Nuccetelli F, Ciani N, Pasini A. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry. 1995;28(3):73-76.
19. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disabilities. J Child Adolesc Psychopharmacol. 2001;11(3):267-77.
20. Rojahn J, Borthwick-Duffy SA. The association between psychotic diagnoses and severe behavior problems in mental retardation. Ann Clin Psychiatry. 1993;5(3):163-170.
21. Craft M, Ismail IA, Krishnamurti D, et al. Lithium in the treatment of aggression in mentally handicapped patients. A double blind trial. Br J Psychiatry. 1987;150:685-689.
22. Poindexter AR, Cain NN, Clarke DJ, et al. Mood stabilizers. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus, OH: Ohio State University Nisonger Center; 1998:215-229.
23. Pary RJ. Towards defining adequate lithium trials for individuals with mental retardation and mental illness. Am J Ment Retard. 1991;95(6):681-691.
24. Tyrer SP, Walsh A, Edwards DE, Berney TP, Stephens DA. Factors associated with good response to lithium in aggressive mentally handicapped students. Progr Neuropsychopharmacol Biol Psychiatry. 1984;8(4-6):751-755.
25. Roach ES, Delgado M, Anderson L, Iannaccone ST, Burns DK. Carbamazepine trial for Lesch-Nyhan self-mutilation. J Child Neurol. 1996;11(6):476-478.
26. Kastner T, Friedman DL, Plummer AT, Ruiz MQ, Henning D. Valproic acid for the treatment of children with mental retardation and mood symptomatology. Pediatrics. 1990;86(3):467-472.
27. Ruedrich S, Swales TP, Fossaceca C, Toliver J, Rutkowski A. Effect of divalproex sodium on aggression and self-injuriousjurous behavior in adults with intellectual disabilities: a retrospective review. J Intell Disabil Res. 1999;43(Pt2):105-111.
28. Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK. Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol. 2002;5(2):141-145.
29. Kalachnik JE, Hanzel TE, Harder SR, Bauernfeind JD, Engstrom EA. Antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavioral measurement techniques. Ment Retard. 1995;33(6):374-382.
30. Stavrakaki C, Antochi R, Summers J, Adamson J. Psychopharmacological treatments in persons with developmental disabilities (DD). In: Griffiths DM, Stavrakaki C, Summers J, eds. Dual Diagnosis: An Introduction to the Mental Health Needs of Persons With Developmental Disabilities. Sudbury, ON: Habilitative Mental Health Resource Network; 2002:239-281.
31. Lloyd KG. Hornykiewicz O, Davidson L. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Eng J Med. 1981;305(19):1106-1111.
32. King BH, Cromwell HC, Lee HT, et al. Dopaminergic and glutamatergic interactions in the expression of self-injuriousjurous behavior. Dev Neurosci. 1998;20(2-3):180-187.
33. Baumeister AA, Sevin JA, King BH. Neuroleptic medications. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus, OH: Ohio State University Nisonger Center; 1998:133-150.
34. Aman MG, Teehan CJ, White AJ, Turbott SH, Vaithianathan C. Haloperidol treatment with chronically medicated residents: dose effects on clinical behavior and reinforcement contingencies. Am J Mental Retard. 1989;93(4):452-460.
35. Baumeister AA, Todd ME, Sevin JA. Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation. Clin Neuropharmacol. 1993;16(4):271-294.
36. Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet. 1999;354(9174):233-242.
37. Spivak B, Mozes T, Mester R, Kodelik M, Weizman A. Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study. J Child Adolesc Psychopharmacol. 2001;11(3):279-284.
38. Malt UF, Nystad R, Bache T, et al. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioral disturbances in learning disabled patients. Br J Psychiatry. 1995;166(3):374-377.
39. Khan BU. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. J Autism Dev Disord. 1997;27(4):479-489.
40. Zarcone JR, Hellings JA, Crandall K, et al. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard. 2001;106(6):525-538.
41. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord. 1997;27(3):313-323.
42. Cohen SA, Ihrig K, Lott RS, Kerrick JM. Risperidone for aggression and self-injuriousjurous behavior in adults with mental retardation. J Autism Dev Disord. 1998;28(3):229-233.
43. Valdovinos MG, Napolitano DA, Zarcone JR, et al. Multimodal evaluation of risperidone for destructive behavior: functional analysis, direct observations, rating scales, and psychiatric impressions. Exp Clin Psychopharmacol. 2002;10(3):268-275.
44. Vanden Borre R. Vermote R, Buttiens M, Thiry P. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1993;87(3):167-171.
45. Zarcone JR, Hellings JA, Crandall K, et al. Effects of risperidone on aberrant behaviour of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard. 2001;106(6):525-538.
46. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239-248.
47. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321.
48. McDonough M, Hillery J, Kennedy N. Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disabilities. J Intellect Disabil Res. 2000;44(Pt 6):677-684.
49. Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry. 2003;64(10):1258-1265.
50. Stavrakaki C, Antochi R, Emery PC. Olanzapine in the treatment of pervasive developmental disorder: a case series. J Psychiatry Neurosci. 2004;29(1):57-60.
51. Cohen SA, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry. 1994;55(10):440-444.
52. Hammock R, Levine WR, Schroeder SR. Brief report: effects of clozapine on self-injuriousjurous behavior of two risperidone non-responders with mental retardation. J Autism Dev Disord. 2001;31(1):109-113.
53. Richardson MA, Haugland G, Pass R, Craig TJ. The prevalence of tardive dyskynesia in a mentally retarded population. Psychopharmacol Bull. 1986;22(1):243-249.
54. Villalba R, Harrington CJ. Repetitive self-injurious behavior: a neuropsychiatric perspective and review of pharmacologic treatments. Semin Clin Neuropsychiatry. 2000;5(4):215-226.
55. Buzan RD, Dubovsky SL, Treadway JT, Thomas M. Opiate antagonists for recurrent self-injurious behavior in three mentally retarded adults. Psychiatr Serv. 1995;46(5):511-512.
56. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, van England H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies. Arch Gen Psychiatry. 1995;52(9):766-773.
57. Casner JA, Weinheimer B, Gualtieri CT. Naltrexone and self-injurious behavior: a retrospective population study. J Clin Psychophannacol. 1996;16(5):389-394.
58. Kennes D, Odberg FO, Bouquet Y, De Rycke PH. Changes in naloxone and haloperidol effects during the development of captivity-induced jumping stereotypy in bank voles. Eur J Pharmacol. 1988;153(1):19-24.
59. Symons FJ, Tapp J, Wulfsberg A, et al. Sequential analysis of the effects of naltrexone on the environmental mediation of self-injurious behavior. Exp Clin Psychopharmacol. 2001;9(3):269-276.
60. Fraser WI, Ruedrich S, Kerr M, Levitas A. Beta-adrenergic blockers. In: Reiss S, Aman MG eds. Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus, OH: Ohio State University Nisonger Center; 1998:271-289.
61. Ruedrich SL, Grush L, Wilson J. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Am J Ment Retard. 1990;95(1):110-119.
62. Madrid AL, State MW, King BH. Pharmacologic management of psychiatric and behavioral symptoms in mental retardation. Child Adolesc Psychiatr Clin N Am. 2000;9(1):225-243.
63. Antochi R, Stavrakaki C, Emery PC. Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities. Post Med J. 2003;79(929):139-146.
64. Gardner WI. A contextual view of nonspecific behavioral symptoms in persons with a dual diagnosis: a psychological model for selecting and monitoring drug interventions. Psychology in Mental Retardation. 1996;21:6-11.
65. Gardner WI, Whalen JP. Discussion: a multi-modal behavior analytic model for evaluating the effects of medical problems on nonspecific behavioral symptoms in persons with developmental disabilities. Behavioral Interventions. 1996;11:147-161.
66. Tsiouris JA, Cohen IL, Patti PJ, Korosh WM. Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injuriousjurious behavior. J Clin Psychiatry. 2003;64(9):1081-1090.